Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
Date:11/5/2010

forts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor StatementThis press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031, LX1032, LX1033, LX2931, and LX4211, including characterizations of the results of and projected timing of clinical trials of such compounds, and the potential therapeutic and commercial potential of LX1031, LX1032, LX1033, LX2931, and LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX1031, LX1032, LX1033, LX2931, and LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Unless specifically indicated otherwise, results reported as trends were not statistically significant. I
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
2. Lexicon to Present at Morgan Stanley Global Healthcare Conference
3. Lexicon to Present at Two Major Healthcare Investor Conferences
4. Lexicon Announces Pricing of Common Stock in Public Offering
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
6. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
7. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
9. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
10. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
11. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 The ... such as its definition, classification, application and ... specification, manufacturing process, and product cost structure. ... applications. The analysis also covers upstream raw ... industry development trend and proposals. In the ...
(Date:12/24/2014)... Diego, CA (PRWEB) December 23, 2014 ... where their Twitter followers can submit their #HolidayInTheLab ... themselves and their lab mates. , For those struggling ... lab mates, the Pipette.com Holiday in the Lab Contest ... Pipette.com Twitter followers to send pictures of ...
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... YORK , Dec. 23, 2014  NeuroLifeSciences announced ... mazindol in children with attention deficit/hyperactivity disorder published in ... . The paper, titled "Pilot Phase ... disorder" ( Konofal et al, Drug Des ... ) shows that mazindol might be an effective, ...
Breaking Biology Technology:Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... , ATLANTA and LONDON, Sept. 10 ... biological medical device and cardiovascular tissue processing company, today announced the ... Matrix, which received CE mark approval in August 2009. BioFoam was ... supplemental measure to promote hemostasis (a complex process that stops bleeding) ...
... WATERTOWN, Mass., Sept. 10 Tetraphase Pharmaceuticals ... technology announced today that it will present three (3) ... and antibacterial activity of analogs from several novel classes ... Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in ...
... BALTIMORE, Sept. 10 Champions Biotechnology, Inc. ... oncology services division assists physicians by providing personalized treatment options ... with PinnacleCare , the pioneer and the ... , PinnacleCare will offer Champions, personalized oncology services ...
Cached Biology Technology:CryoLife Announces First Clinical Use of BioFoam(R) 2CryoLife Announces First Clinical Use of BioFoam(R) 3CryoLife Announces First Clinical Use of BioFoam(R) 4CryoLife Announces First Clinical Use of BioFoam(R) 5Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 3Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 4
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into ... key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security ... an end to the frustration that comes with usernames, passwords ... a user,s smartphone to acquire his or her biometrics to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... July 23, 2013 The goal of smart cities ... performance, efficiency and functionality. This is expressed through an ... of the overall city experience.  Cities are hoping to ... city projects to ultimately drive economic growth. Some key ...
... in the July issue of the Journal of ... super-infections like pneumonia with influenza. The research was led ... infectious disease specialist who is also chair of the ... Science Center and adjunct faculty at St. Jude Children,s ...
... NY. -- The use of central nervous system fetal ... cells for transplantation procedures aimed at restoring damage done ... tissue microbial contaminants have been known to cause brain ... team from Germany has developed a "washing" technique that ...
Cached Biology News:Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 2Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 3Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 4Frost & Sullivan: Moving the Smart Cities Idea from Concept to Reality 5New protocol developed to decontaminate human fetal tissues used for cell transplantation 2
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
... Cloning is the most ... cloning PCR products. TOPO ... Blunt TOPO vectors are ... with topoisomerase I. This ...
... TOPO Cloning is the ... for cloning PCR products. ... Zero Blunt TOPO vectors ... activated with topoisomerase I. ...
ready-to-use solution...
Biology Products: